Skip to main content
SpringerLink
Log in

Possible hepatitis B reactivation with direct-acting antivirals

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. daclatasvir [Daklinza], dasabuvir [Exviera], elbasvir/grazoprevir [Zepatier], ombitasvir/paritaprevir/ritonavir [Viekirax], simeprevir [Olysio], sofosbuvir [Sovaldi], sofosbuvir/ledipasvir [Harvoni] or sofosbuvir/velpatasvir [Epclusa]

References

  1. European Medicines Agency. Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B. Internet Document : 16 Dec 2016. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/12/news_detail_002669.jsp&mid=WC0b01ac058004d5c1.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Possible hepatitis B reactivation with direct-acting antivirals. Reactions Weekly 1633, 9 (2017). https://doi.org/10.1007/s40278-017-24280-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-24280-5

Search

Navigation